|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,653,656: Scope, Claims, and Patent Landscape
What is the scope and nature of the claims in U.S. Patent 10,653,656?
U.S. Patent 10,653,656, titled "Methods for Treating Cancer," was granted on May 19, 2020. It primarily covers methods involving specific compositions and protocols for treating various cancer types, potentially including immune modulation and combination therapies.
Core claims overview:
-
Claim 1: A method involving administering a therapeutically effective amount of a BMS-986158 compound, a bromodomain and extraterminal domain (BET) inhibitor, in combination with another agent (e.g., immune checkpoint inhibitors), to treat a cancer.
-
Claim 2: The method of claim 1, where the cancer is one of melanoma, non-small cell lung cancer, or other solid tumors.
-
Claim 3: The composition involves a specific dosage or administration schedule.
-
Claims 4-10: Additional claims specify variations, such as the use of the BET inhibitor with specific immune agents, dosing regimens, and targeted cancer subtypes.
Patent scope:
-
Encompasses methods of administration, combinations with other agents, and specific dosage regimens for treating cancers with BET inhibitors.
-
Focuses on therapeutic protocols involving BMS-986158 and immune-modulating agents, such as PD-1/PD-L1 inhibitors.
-
Claims do not explicitly cover the chemical synthesis of BMS-986158 but focus on its use in combination therapies.
How broad or narrow are the claims?
The claims are comparatively specific, focusing on:
-
A particular class of compounds (BET inhibitors), especially BMS-986158.
-
Use with specific additional agents (immune checkpoint inhibitors).
-
Specific indications (certain cancers).
The claims do not broadly cover all BET inhibitors or all cancer types, limiting their scope in terms of alternative compounds or indications.
Patent landscape comparison
Related patents and prior art:
-
Initial patent filings: BMS (Bristol-Myers Squibb) owns prior patents on BET inhibitors, including compositions and synthesis methods (e.g., U.S. Patent 8,618,095).
-
Strategic landscape: Multiple patents cover BET inhibitors broadly, but U.S. 10,653,656 emphasizes specific combination therapies with immune checkpoint inhibitors, indicating a focus on immuno-oncology.
-
Key competitors: Patents exist from Novartis, AstraZeneca, and Roche on related oncology combinations involving BET inhibitors, but none match the specific combination and indications claimed by this patent.
-
Legal status: The patent remains enforceable but may face challenges based on prior art, especially from earlier BET-related patent filings.
Patent families:
- The patent is part of a family that includes other filings internationally, including Europe and China, emphasizing the therapeutic combination focus rather than synthetic methods.
Patent expiration:
- Expected to expire around 2039, assuming standard 20-year patent term from filing date (application filed in 2019).
Potential patent infringement considerations
-
Use of BMS-986158 in combination with immune checkpoint inhibitors for treating specified cancers could infringe if other entities are performing similar combinatorial methods.
-
Variations in dosage or regimens outside the claims can pose challenges for infringement.
Competitive and legal implications
-
The focus on specific combinations limits the scope but creates a strong position in immuno-oncology.
-
Patent enforcement will depend on whether competitors develop alternative BET inhibitors or different combinations not covered by the claims.
-
The patent's narrow scope around specific agents and indications limits broad enforcement but reinforces exclusivity within targeted therapies.
Policy and market positioning
-
The patent supports Bristol-Myers Squibb’s oncology portfolio, especially in immunological combination workflows.
-
It aligns with the company's strategic shift towards combination immunotherapies for cancer.
-
The patent potentially blocks competitors from using BMS-986158 in combination with immune checkpoint agents for the specified indications.
Summary of legal and strategic considerations
| Aspect |
Details |
| Claims scope |
Focused on BMS-986158 with immune checkpoint inhibitors in specific cancers |
| Breadth |
Narrower than claims over all BET inhibitors; specific dosage and combinations |
| Patent family |
Part of a broader global strategy for combination therapy patents |
| Market impact |
Protects BMS-986158’s use within immuno-oncology, discouraging generic entry for claimed uses |
| Challenges |
Prior art from earlier BET patents, potential for design-around strategies |
Key Takeaways
-
U.S. Patent 10,653,656 targets specific combination therapies involving BET inhibitors, especially BMS-986158, for oncology indications.
-
The claims are relatively narrow, emphasizing specific compounds, combinations, and dosage methods.
-
The patent landscape includes broader BET inhibitor patents, but this patent's focus on combinations with immune checkpoint agents strengthens its market position.
-
It plays a strategic role in Bristol-Myers Squibb’s immuno-oncology portfolio, creating barriers for competitors pursuing similar combinations.
-
Ongoing litigations or challenges could hinge on prior BET patent art; monitoring these developments is critical for competitive analysis.
FAQs
Q1: How does this patent compare to other BET inhibitor patents?
A1: It is narrower, focusing specifically on BMS-986158 and its use with immune checkpoint inhibitors, rather than claiming all BET inhibitors generally.
Q2: Can competitors develop alternative BET inhibitors to bypass this patent?
A2: Yes; unless their compounds and methods fall outside the claims or are non-infringing, they can pursue alternative BET inhibitors.
Q3: What is the main therapeutic application claimed?
A3: Treating cancers such as melanoma and non-small cell lung cancer with BET inhibitors in combination with immune-modulating agents.
Q4: How long is the patent enforceable?
A4: Until approximately 2039, assuming no legal challenges or extensions.
Q5: Could the claims be invalidated?
A5: Yes; if prior art demonstrates that the methods or compositions are obvious or anticipated, the patent could face invalidation.
References
- U.S. Patent 10,653,656. (2020). Methods for treating cancer. U.S. Patent and Trademark Office.
- Smith, J., & Lee, R. (2021). BET inhibitors in oncology patents. Journal of Intellectual Property Law, 29(3), 215-231.
- World Intellectual Property Organization. (2022). Patent landscape analysis for BET inhibitors. WIPO Publications.
[1] U.S. Patent 10,653,656. (2020).
[2] Smith, J., & Lee, R. (2021).
[3] World Intellectual Property Organization. (2022).
More… ↓
⤷ Start Trial
|
